Julieta Corral1, Josep Maria Borràs2, Pietro Chiarello3, Enric García-Alzorriz3, Francesc Macià4, Anna Reig3, Javier Mateu de Antonio3, Xavier Castells4, Francesc Cots4. 1. Programa de Doctorado en Salud Pública, Departament de Pediatria, d'Obstetrícia i Ginecologia, Medicina Preventiva i Salut Pública, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, España; Plan Director de Oncología, Departament de Salut, Generalitat de Catalunya, Barcelona, España; Departamento de Ciencias Clínicas, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, España. Electronic address: jcorral@iconcologia.net. 2. Plan Director de Oncología, Departament de Salut, Generalitat de Catalunya, Barcelona, España; Departamento de Ciencias Clínicas, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, España. 3. Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España. 4. Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), España.
Abstract
OBJECTIVE: To assess the hospital cost associated with colorectal cancer (CRC) treatment by stage at diagnosis, type of cost and disease phase in a public hospital. METHODS: A retrospective analysis was conducted of the hospital costs associated with a cohort of 699 patients diagnosed with CRC and treated for this disease between 2000 and 2006 in a teaching hospital and who had a 5-year follow-up from the time of diagnosis. Data were collected from clinical-administrative databases. Mean costs per patient were analysed by stage at diagnosis, cost type and disease phase. RESULTS: The mean cost per patient ranged from 6,573 Euros for patients with a diagnosis of CRC in situ to 36,894 € in those diagnosed in stage III. The main cost components were surgery-inpatient care (59.2%) and chemotherapy (19.4%). Advanced disease stages were associated with a decrease in the relative weight of surgical and inpatient care costs and an increase in chemotherapy costs. CONCLUSIONS: This study provides the costs of CRC treatment based on clinical practice, with chemotherapy and surgery accounting for the major cost components. This cost analysis is a baseline study that will provide a useful source of information for future studies on cost-effectiveness and on the budget impact of different therapeutic innovations in Spain.
OBJECTIVE: To assess the hospital cost associated with colorectal cancer (CRC) treatment by stage at diagnosis, type of cost and disease phase in a public hospital. METHODS: A retrospective analysis was conducted of the hospital costs associated with a cohort of 699 patients diagnosed with CRC and treated for this disease between 2000 and 2006 in a teaching hospital and who had a 5-year follow-up from the time of diagnosis. Data were collected from clinical-administrative databases. Mean costs per patient were analysed by stage at diagnosis, cost type and disease phase. RESULTS: The mean cost per patient ranged from 6,573 Euros for patients with a diagnosis of CRC in situ to 36,894 € in those diagnosed in stage III. The main cost components were surgery-inpatient care (59.2%) and chemotherapy (19.4%). Advanced disease stages were associated with a decrease in the relative weight of surgical and inpatient care costs and an increase in chemotherapy costs. CONCLUSIONS: This study provides the costs of CRC treatment based on clinical practice, with chemotherapy and surgery accounting for the major cost components. This cost analysis is a baseline study that will provide a useful source of information for future studies on cost-effectiveness and on the budget impact of different therapeutic innovations in Spain.
Keywords:
Colorectal neoplasms; Costes de hospital; Costes de la atención en salud; Estudios retrospectivos; Health care costs; Health resources; Hospital costs; Neoplasias colorrectales; Recursos en salud; Retrospective studies
Authors: Ana C Montesinos Gálvez; Francisco Jódar Sánchez; Carmen Alcántara Moreno; Antonio J Pérez Fernández; Rosario Benítez García; Mercedes Coca López; María Paz Bienvenido Ramírez; Monserrat Cabrera López; Luisa Vázquez Burrero; Pilar Jurado Berja; Raquel Sánchez García; Josefa Martín Cebrián; María Luz Hervas García; Remedios López Fernández; Claudia Pérez Jiménez; María Antonia Reyes Vico; Ana Belén Vargas Villegas; Nuria García-Agua Soler; Antonio J García Ruiz Journal: Int J Environ Res Public Health Date: 2020-08-13 Impact factor: 3.390
Authors: Sherley Diaz-Mercedes; Ivan Archilla; Jordi Camps; Antonio de Lacy; Iñigo Gorostiaga; Dulce Momblan; Ainitze Ibarzabal; Joan Maurel; Nuria Chic; Josep Antoni Bombí; Francesc Balaguer; Antoni Castells; Iban Aldecoa; Josep Maria Borras; Miriam Cuatrecasas Journal: Appl Health Econ Health Policy Date: 2019-10 Impact factor: 2.561